Psychotic Disorders Research Program
The Psychotic Disorders Research Program is interested in the study and treatment of adult patients with schizophrenia and bipolar disorder. The clinical and translational studies include trials of novel treatments and studies of cognition, genetics, imaging, and neurochemistry. The basic research includes microdialysis and behavioral studies.
Directors: Stephan Heckers, MD and Herbert Meltzer, M.D.
Faculty
Yeujin Chen, M.D.
Samet Kose, M.D., Ph.D.
Zhu Li, Ph.D.
Jeffrey Stovall, M.D.
Tianlai Tang, M.D.
David Weinstein, M.D.
Neil Woodward, Ph.D.
Staff
Kristan Armstrong
Jin Dai
Patrick Gallagher
Mei Huang
Karuna Jayathilake
Melissa Ott
Kara Watts
Austin Woolard
Projects
1. Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors
2. Quantifying abnormalities in cortical activation associated with auditory hallucinations using functional magnetic resonance imaging
3. Estimating and Reducing the Cardiovascular Risk of Patients with Schizophrenia from Lipid Measures and Ischemic Electrocardiographic Changes
4. Does the Addition of Divalproex ER to an Atypical Antipsychotic Drug Improve Cognition and Psychopathology in Outpatients with Schizophrenia or Schizoaffective Disorder?
5. Effect of Addition of Armodafinil on the Tolerability and Efficacy for Cognition of Atypical Antipsychotic Drugs in Patients with Schizophrenia or Schizoaffective Disorder
6. A Multicenter, Randomized, Double-blind placebo-controlled, 16-week study of Aripiprazole Used as Dual Therapy in the Treatment of Patients with Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine or Risperidone Monotherapy
